These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31149041)

  • 1. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer.
    Park SH; Jo MJ; Kim BR; Jeong YA; Na YJ; Kim JL; Jeong S; Yun HK; Kim DY; Kim BG; Kang SH; Oh SC; Lee DH
    Theranostics; 2019; 9(8):2235-2251. PubMed ID: 31149041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
    Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
    J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant activation of hedgehog signaling promotes cell proliferation via the transcriptional activation of forkhead Box M1 in colorectal cancer cells.
    Wang D; Hu G; Du Y; Zhang C; Lu Q; Lv N; Luo S
    J Exp Clin Cancer Res; 2017 Feb; 36(1):23. PubMed ID: 28148279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
    Du F; Qiao C; Li X; Chen Z; Liu H; Wu S; Hu S; Qiu Z; Qian M; Tian D; Wu K; Fan D; Nie Y; Xia L
    Theranostics; 2019; 9(13):3879-3902. PubMed ID: 31281520
    [No Abstract]   [Full Text] [Related]  

  • 5. Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells.
    Po A; Citarella A; Catanzaro G; Besharat ZM; Trocchianesi S; Gianno F; Sabato C; Moretti M; De Smaele E; Vacca A; Fiori ME; Ferretti E
    Sci Rep; 2020 Aug; 10(1):13988. PubMed ID: 32814794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
    Bora-Singhal N; Perumal D; Nguyen J; Chellappan S
    Neoplasia; 2015 Jul; 17(7):538-51. PubMed ID: 26297432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
    Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
    Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcription factor POU4F2 promotes colorectal cancer cell migration and invasion through hedgehog-mediated epithelial-mesenchymal transition.
    Guo K; Wang P; Zhang L; Zhou Y; Dai X; Yan Y; Chen Y; Wasan HS; Yu J; Ruan S; Sun L
    Cancer Sci; 2021 Oct; 112(10):4176-4186. PubMed ID: 34327778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activating CCT2 triggers Gli-1 activation during hypoxic condition in colorectal cancer.
    Park SH; Jeong S; Kim BR; Jeong YA; Kim JL; Na YJ; Jo MJ; Yun HK; Kim DY; Kim BG; Lee DH; Oh SC
    Oncogene; 2020 Jan; 39(1):136-150. PubMed ID: 31462707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of EphB3 in gastric cancer with acquired resistance to a FGFR inhibitor.
    Lee SY; Na YJ; Jeong YA; Kim JL; Oh SC; Lee DH
    Int J Biochem Cell Biol; 2018 Sep; 102():128-137. PubMed ID: 30044964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of the EPHB3 tumor-suppressor gene in human colorectal cancer through decommissioning of a transcriptional enhancer.
    Jägle S; Rönsch K; Timme S; Andrlová H; Bertrand M; Jäger M; Proske A; Schrempp M; Yousaf A; Michoel T; Zeiser R; Werner M; Lassmann S; Hecht A
    Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4886-91. PubMed ID: 24707046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.
    Rosa R; Marciano R; Malapelle U; Formisano L; Nappi L; D'Amato C; D'Amato V; Damiano V; Marfè G; Del Vecchio S; Zannetti A; Greco A; De Stefano A; Carlomagno C; Veneziani BM; Troncone G; De Placido S; Bianco R
    Clin Cancer Res; 2013 Jan; 19(1):138-47. PubMed ID: 23166225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
    Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
    Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CBC-1 as a Cynanbungeigenin C derivative inhibits the growth of colorectal cancer through targeting Hedgehog pathway component GLI 1.
    Chen J; Chen W; Li X; Ye Y; Huang W; Gao L; Zhang M
    Steroids; 2024 Jun; 206():109421. PubMed ID: 38614233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors.
    Gelfo V; Rodia MT; Pucci M; Dall'Ora M; Santi S; Solmi R; Roth L; Lindzen M; Bonafè M; Bertotti A; Caramelli E; Lollini PL; Trusolino L; Yarden Y; D'Uva G; Lauriola M
    Oncotarget; 2016 Nov; 7(44):72167-72183. PubMed ID: 27708224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab enhances the anti-tumor function of macrophages in an IL-6 dependent manner.
    Zhao Y; Liu X; Huo M; Wang Y; Li Y; Xu N; Zhu H
    Life Sci; 2021 Feb; 267():118953. PubMed ID: 33359746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
    Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
    Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.